Labcorp Announces First Quarter 2026 Results and Raises Full Year Guidance

Labcorp Holdings Inc. reported strong first-quarter 2026 results, with revenue increasing by 5.8% to $3.54 billion and diluted EPS rising by 32.8% to $3.35. Adjusted EPS saw a 10.6% increase to $4.25. The company raised its full-year 2026 guidance, projecting enterprise revenue growth of 5.0% to 6.1% and adjusted EPS between $17.70 and $18.35. Key growth drivers included advancements in specialty and companion diagnostics, expanded collaborations with health systems, and the integration of AI technologies. Labcorp highlighted strategic initiatives such as collaborations with Children’s Hospital of Philadelphia, Illumina, and PathAI, alongside the launch of new products like the Labcorp Fentanyl Visual Urine Test and the upcoming MyLabcorp mobile app. The company also reported significant capital allocation, investing $202.2 million in acquisitions, repurchasing $98.0 million in stock, and paying $61.2 million in dividends during the quarter.